Rockwell Medical surges as partner gets S.Korea approval for Triferic injection

Jeil Pharmaceutical

13/01/2022 14:04

** Shares of biopharmaceutical firm  RMTI.O  up 38% at a
near three-month high of 56 cents premarket
    ** Co says its partner Jeil Pharmaceutical received approval
from South Korean authorities for its Triferic injection, which
is used as an iron supplementation therapy and for maintaining
hemoglobin in adult patients with chronic kidney disease
 urn:newsml:reuters.com:*:nGNX7M45Hm
    ** Jeil has exclusive rights to commercialize Rockwell
Medical's Triferic in the Asian country 
    ** In consideration for the license, Rockwell Medical has
received an upfront fee and will be eligible for milestone
payments and royalties on net sales
    ** Product sales are anticipated to begin in June/July of
2022
    ** Triferic is the only U.S. FDA-approved therapy to replace
iron and maintain hemoglobin in patients
    ** RMTI is the biggest premarket gainer on the Nasdaq index 


 (Reporting by Shashank Nayar in Bengaluru)
 ((Shashank.Nayar@thomsonreuters.com; within U.S. +1 646 223
8780; outside U.S. +91 80 6182 2256;))